Eli Lilly takes aim at weight-loss drug copies with new ad campaign
Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...
ADWEEK on MSN2h
Mounjaro Maker Eli Lilly Swipes at Unapproved GLP-1 Rivals in Oscars Ad
Eli Lilly's bet on the Oscars shows the GLP-1 ad wars are heating up. - Eli Lilly. At the 2024 Academy Awards, Eli Lilly, the ...
MM&M4h
Faced with compounded drugs, Eli Lilly tells consumers to ‘be a healthy skeptic’
Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.
Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due In Q2
Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...
India's Sun Pharma aims to launch its obesity drug in five years, managing director says
India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...
This Could Be the Best GLP-1 Stock to Buy in 2025
The GLP-1 weight loss market is a massive one, with some analysts expecting it to be worth around $200 billion by 2031. Hype ...
pharmaphorum19h
Algiax non-opioid drug works in chronic neuropathic pain
The phase 2a trial showed rapid onset as well as long-lasting pain reduction with Algiax's allosteric GABAA-receptor modulator AP-325, setting up further trials of the drug. Neuropathic pain can ...